Press & News

The next generation biopharmaceuticals

Press releases 2015

2015-12-24

Affibody Licenses Albumod™ Half-life Extension Technology to MedImmune

Solna, Sweden, December 24, 2015. Affibody AB today announced that MedImmune has extended its Albumod™ platform licensing agreement[read more]

Older press releases

2015-12-01

Affibody receives clinical milestone from Daiichi Sankyo

Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.[read more]

2015-11-20

Interim Report – January to September 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its its Interim Report for the third quarter...[read more]

2015-08-21

Interim Report – January to June 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its its Interim Report for the second quarter...[read more]

Affibodys latest Press releases

2020-02-03

Notice of EGM (Kallelse till extra bolagsstämma)

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 17 februari 2020 kl 14.00 i...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q3 (Nov. 15, 2019)

Investor information